Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2075029 | 0.84 | JAK2 (0.42) | KDM4ERAB9AHPGDKMT2ANR4A2 | |
| SCHEMBL2075809 | 0.81 | NPC1 (0.38) | KDM4ERAB9AHPGDKMT2ANR4A2 | |
| SCHEMBL6362764 | 0.77 | MAPT (0.41) | PIK3CGKDM4ERAB9AHPGDALDH1A1 | |
| SCHEMBL2076088 | 0.77 | NR4A2 (0.35) | KDM4ERAB9ANR4A2ALDH1A1POLB | |
| SCHEMBL4800941 | 0.76 | NPC1 (0.40) | ALDH1A1NPC1 | |
| SCHEMBL4166886 | 0.76 | RAB9A (0.51) | KDM4ERAB9AHPGDKMT2ANR4A2 | |
| SCHEMBL4163033 | 0.76 | ALDH1A1 (0.54) | PIK3CGKDM4ERAB9AHPGDKMT2A | |
| SCHEMBL4159114 | 0.75 | NR4A2 (0.33) | KDM4ERAB9AHPGDNR4A2ALDH1A1 | |
| SCHEMBL4164802 | 0.74 | NPC1 (0.52) | KDM4ERAB9AHPGDKMT2ANR4A2 | |
| SCHEMBL4167886 | 0.73 | NPC1 (0.65) | KDM4ERAB9AHPGDKMT2ANR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CDK2, CDK4, CDK20 | PIK3CG 338/4885KDM4E 2234/4885RAB9A 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.